Previous Article |
Table of Contents
| Next Article
Laboratory of Biochemistry and Molecular Biology, The
Rockefeller University, 1230 York Avenue, New York, NY 10021
The general transcription initiation factor TFIID was originally
identified, purified, and characterized with a biochemical assay in
which accurate transcription initiation is reconstituted with multiple,
chromatographically separable activities. Biochemical analyses have
demonstrated that TFIID is a multiprotein complex that directs
preinitiation complex assembly on both TATA box-containing and
TATA-less promoters, and some TFIID subunits have been shown to be
molecular targets for activation domains in DNA-binding regulatory
proteins. These findings have most commonly been interpreted to support
the view that transcriptional activation by upstream factors is the
result of enhanced TFIID recruitment to the core promoter. Recent
insights into the architecture and cell-cycle regulation of the
multiprotein TFIID complex prompt both a reassessment of the functional
role of TFIID in gene activation and a review of some of the less
well-appreciated literature on TFIID. We present a speculative model
for diverse functional roles of TFIID in the cell, explore the merits
of the model in the context of published data, and suggest experimental
approaches to resolve unanswered questions. Finally, we point out how
the proposed functional roles of TFIID in eukaryotic class II
transcription fit into a model for promoter recognition and activation
that applies to both eubacteria and eukaryotes.
TFIID and Transcription Activation
The initial description of TFIID (1) was followed by early
biochemical studies that identified it as the "TATA box-recognition factor" and focused on its interactions with the core promoter (2,
3). Nuclease and chemical footprinting techniques revealed two
different types of DNA interaction patterns by a highly purified human
TFIID preparation. One (on the Ad2ML promoter) extends over a broad
region from nucleotide positions The first studies implicating TFIID as a target for transcriptional
activators employed partially purified natural TFIID and demonstrated
that activator proteins could have both quantitative and qualitative
effects on TFIID-promoter binding (3, 13-15). Comparison of
recombinant TBP with natural TFIID preparations in functional assays
provided strong evidence that a multiprotein TFIID complex, but not TBP
alone, can mediate activator-dependent transcription in
vitro and suggested coactivator functions for TAFs (16-18).
Furthermore, the availability of TAFs in recombinant form led to the
in vitro demonstration of selective physical interactions with specific activators (reviewed in ref. 19). The functional significance of these interactions is supported by in vitro
correlations of activator function with the capability to interact with
TAFs (based on activator mutagenesis and anti-TAF antibody inhibition studies) and with the presence of the interacting TAF(s) in functional TFIID complexes (20-25). Recent genetic experiments similarly
demonstrate the importance of particular activator-TAF interactions in
transcriptional enhancement of specific genes in the
Drosophila embryo (26), whereas studies in yeast have
suggested that TAFs are not generally required for the activation of
many genes (refs. 27 and 28; reviewed in ref. 29).
Although the ability to reconstitute partial and complete recombinant
TFIID complexes (23) provides the means for examining mechanistic
possibilities of TAFII coactivator functions in
vitro, a high degree of transcriptional activation in
vitro also requires additional coactivators that are not tightly
associated with TFIID and that are only in part biochemically defined
(30). In addition, the absence in purified transcription systems of
natural restrictions, such as TBP-interacting negative cofactors
(reviewed in ref. 30) and packaging of DNA within chromatin, may give
rise to in vitro phenomena, such as activator-independent
basal transcription, that have no in vivo correlates (10).
Activation Mechanisms: Direct vs.
Indirect
Transcriptional activators appear to function both in
vitro and in vivo by increasing the rate of
transcription initiation, elongation or both (31, 32). On the basis of
eubacterial studies (33) it is thought that initiation rates can be
modulated at several steps that include preinitiation complex (PIC)
formation, isomerization of the resulting complex, and promoter
clearance.
In eukaryotes the assembly of a functional class II PIC involves the
binding of at least six well-characterized general transcription factors (GTFs), RNA polymerase II and other cofactors to the core promoter region in an ordered fashion. This may involve multiple, sequential steps that have been characterized by in vitro
binding experiments (reviewed in ref. 10) or the recruitment of a
preassembled holo-RNA polymerase that may contain a subset of GTFs
(reviewed in ref. 34). Activators may enhance the formation of a
functional PIC by a "direct" mechanism that involves interactions
with free GTFs (including TFIID) and/or a holoenzyme complex that
effectively recruit these components to the core promoter.
Alternatively, they may act by an "indirect" mechanism that
involves interactions with, and modifications of, a preexisting
TFIID-core promoter complex that in turn mediate recruitment of the
other components. (Both mechanisms may be facilitated or mediated by
coactivator proteins.)
The idea that activators could function "directly" by recruiting
TFIID to the core promoter originated in the observation that the
upstream activator USF and partially purified TFIID can mutually
stabilize their respective DNA interactions (3) and was supported by
studies with the pseudorabies activator IE (13, 14). A later
demonstration that the herpes virus activator VP16 can interact with
the TBP subunit of TFIID (35) inaugurated a host of similar studies,
some of which indeed indicated TBP-mediated activator function (refs.
36 and 37; reviewed in ref. 38). More recently, studies employing
partially reconstituted TFIID complexes have provided evidence that the
synergistic action of multiply bound activators (39) can be explained
by recruitment of TFIID through specific activator-TAFII
interactions in vitro (23, 40, 41).
Curiously, however, an activation mechanism based solely on TFIID
recruitment seems at odds with the observed high stability of
TFIID-DNA complexes that (at least on several promoters) are refractory to both template challenge (42-44) and nucleosomal
repression (45). It is worth emphasizing that in vitro
assays that employ nonsaturating concentrations of TFIID may exaggerate
the effects of activator-dependent recruitment of TFIID and,
consequently, overshadow alternative TFIID-mediated activator effects.
Thus the operative in vitro activation mechanism may depend
crucially on the particular experimental design.
One alternative activation mechanism posits TFIID as a mediator for
activator-dependent GTF/holoenzyme recruitment. An early mutagenesis
analysis of the Ad EIIa late promoter, for example, showed that
upstream elements do not necessarily act merely to overcome a
rate-limiting step imposed by an inefficient TATA element (46).
Similarly, a mechanistic study on the Ad2 E1B promoter failed to show
any effect of Sp1 binding on the stability of the human TFIID-E1b
promoter complex, but argued instead that a qualitative difference led
to increased initiation rates (47). The same conclusion was drawn in a
study that utilized specific monoclonal antibodies and the detergent
sarkosyl to show that an acidic activator could act through
template-committed complexes containing TFIID and TFIIA to increase the
number of productive PICs (48).
A possible mechanism for such a qualitative difference in
template-committed complexes was suggested by footprinting analyses on
the Ad5E4 promoter. These studies demonstrated that activators can
induce a downstream extension of the normally restricted TFIID footprint, an event that correlated with increased recruitment of other
GTFs and RNA polymerase II and increased transcription initiation (15,
49, 50). These observations indicated an "indirect" activation
mechanism involving an activator-induced conformational change of a
preexisting TFIID-promoter complex that in turn facilitates productive
PIC formation by incoming RNA polymerase II and other GTFs.
In this context, it is noteworthy that some mechanistic studies have
revealed TFIIB incorporation into the PIC as a limiting step in
transcription initiation (51), confirming the relevance of a so-called
"rapid start complex" containing both TFIIB and RNA polymerase II
as an intermediate within the PIC assembly pathway (43). Importantly,
one TFIID subunit, Drosophila TAFII40 (homologue of human TAFII31), was shown to be capable of interacting
with both acidic activation surfaces and with TFIIB (20). Recent analyses of activator function on the Ad5E4 promoter have indeed demonstrated a correlation between the aforementioned activator-induced isomerization of promoter-bound TFIID and functional TFIIB recruitment (52, 53).
Recent Insights in TFIID Structure and Function
Toward a detailed understanding of the role of TFIID in promoter
recognition and PIC formation, crystallographic studies have shown that
specific binding of TBP to the TATA element induces dramatic
distortions of the DNA helix (54, 55). As revealed by subsequent
structural studies of TBP-TATA-TFIIB (56) and TBP-TATA-TFIIA (57,
58) ternary complexes, the unique TBP-TATA structure facilitates
stable interactions of TFIIA and TFIIB that in turn may allow formation
of the complete PIC. More recent biochemical and biophysical studies
have demonstrated that the TFIID complex contains a histone
octamer-like structure consisting of hTAF80, hTAF31, and hTAF20/15
(or dTAF62, dTAF42, dTAF28/22) (59, 60). Studies examining
interactions of recombinant factors and partially disrupted native
human (in vitro) and yeast (in vivo) TFIID
complexes indicate that components of the presumptive TAF octamer are
central to the architecture of the TFIID multiprotein complex (28, 61). The location of several TFIID subunits was recently mapped relative to
Ad2ML promoter DNA sequences by a site-specific photocrosslinking study
(62). The same study also showed that TFIID binding to the Ad2ML
promoter induces negative supercoiling that is mediated by TAFs,
consistent with the earlier observation that TFIID binding to the Ad2ML
promoter DNA results in a DNase I footprinting pattern reminiscent of
nucleosomal DNA wrapping (3, 63).
Interestingly, a number of TFIID-interacting transcriptional cofactors
are related to chromatin components. For example, the negative cofactor
NC2 (Dr1/DRAP1), which can regulate TFIIB access to the
TFIID-promoter complex through binding to TBP in competition with
TFIIA (64-66), is a hetero-dimer that is composed of histone H2A- and
H2B-related subunits and capable of DNA binding (67-69). It is thus
the most recent member of a growing class of transcription cofactors
that were originally described as, or bear structural relationships to,
chromatin-associated proteins; these include topoisomerase I
(PC3/Dr2) (70-72), HMG1 (NC1) (73), HMG2 (74, 75), HMG17 (76), HMG
I(Y) (77), LEF-1 (78), and DSP1 (79). Although the mechanism of
coactivator function for some of these proteins remains to be
elucidated, these observations emphasize the close link between the
structural organization of chromatin around a given start site and the
mechanisms responsible for the precise regulation of transcriptional
initiation at that site. Furthermore, a functional connection has long
been suggested by a yeast genetic screen for utilization of a cryptic
transcription initiation site; it not only yielded mutations in TBP
itself but also in histones and what appear to be regulators of
chromatin structure (e.g., see ref. 80).
Within this context it is of particular interest that an initial
cell-biological study of TFIID revealed that transcriptionally inactive mitotic chromosomes contain significant amounts of TFIID (81),
although mitotic phosphorylation of the DNA-binding domains of some
activator proteins correlates with their DNA dissociation (82). Mitotic
phosphorylation also seems to regulate the activity of the TFIID
complex, but not necessarily via its ability to bind to core promoter
elements (discussed further below). Instead, biochemical data indicate
that multiple serine/threonine phosphorylations of TBP and TAFs
selectively inhibit the ability of TFIID to mediate transcriptional
activation (81), thereby providing an indication that TFIID activity
can be regulated in ways other than through stoichiometric positive or
negative cofactor interactions. Finally, these observations suggest
that some class II promoters may bind TFIID constitutively, and that
transcription initiation may be regulated during the cell cycle by
reversible modifications of TFIID subunits.
A regulatory function of TFIID within the chromatin context is also
suggested by the provocative findings that the largest TFIID subunit,
TAFII250, contains protein kinase (83) and histone acetyltransferase (84) activities. The latter finding follows the
discovery that yeast and human coactivators such as GCN5 (85) and
CBP/p300 (86) contain acetyl-transferase activities that are thought
to be involved in modulating DNA accessibility in chromatin. Given the
existence of a histone-related octamer within TFIID, it is of immediate
interest to characterize the specificity and regulation of these
enzymatic activities.
A New Conceptual Framework for TFIID Function
Components involved in packaging of DNA into chromatin have
coevolved with the factors that constitute the transcription
machineries to fulfill their respective functional requirements in the
eukaryotic cell. Significant progress in our understanding of
transcriptional regulation thus requires consideration The TFIID complex bound to certain class II core promoters may be
regarded as a specialized chromatin component that fulfills the
topological requirements necessary to mediate and maintain the
inducibility of genes. As such, the TFIID-core promoter complex is
capable of conformational changes that allow it to switch from a
transcriptionally inactive state to an active state in a process that
is effected by gene- and cell type-specific activators and that can be
modulated by cofactors or covalent modifications.
In the following sections, we discuss the experimental evidence for
this proposal, indicate developmental and evolutionary aspects, and
suggest experimental approaches to test additional predictions.
Early
in vitro studies showed that TFIID binding to core promoter
DNA is mutually exclusive with nucleosome formation (45). Consistent
with this observation, positioned nucleosomes have been found to
repress class II gene transcription by inhibiting access of the general
transcription machinery to core promoter sequences in vivo.
As an example, permanent inactivation of the cell type-specific STE2
gene in yeast alpha cells correlates with the positioning of a
nucleosome over the TATA box region (87).
However, consistent with the remarkable stability of TFIID-DNA
complexes demonstrated in the earliest characterization of TFIID
in vitro (3, 44), an above-mentioned study (81) demonstrated that TFIID, potentially in promoter complexes, can persist on transcriptionally inactive mitotic chromosomes in vivo.
Evidence for TFIID binding to the core promoter regions of genes that
are transcriptionally inactive is provided by a number of in
vivo footprinting studies. The yeast HSP82 promoter, for example,
exhibits both constitutive occupancy of its core promoter and a
markedly distorted helix that is indicative of TBP binding to the TATA box (88). Similarly, genomic footprinting studies on the
transcriptionally inactive Drosophila H3 (89) and yeast cyc1
(90) genes are indicative of the presence of promoter-bound TFIID.
Taking these data into account, we propose that three states of class
II gene activity can be distinguished, as outlined in Fig.
1. First, promoters not
containing TFIID are transcriptionally inactive (Fig.
1A) and cannot be activated without chromatin
remodeling, a process that, in some cases, could require DNA synthesis
and cell division. Second, so-called "poised genes" are present
in an inactive state but are rapidly inducible; they contain TFIID but
lack activators that could provide the inducing stimulus (Fig. 1B). Third, actively transcribing genes contain TFIID as
well as activators bound to their respective promoter sites (Fig.
1C).
These proposed states of gene activity are illustrated by studies on
the interleukin 2 (IL-2) promoter, which is only active in activated T
lymphocytes. It was demonstrated (91) by in vivo footprinting experiments that the expression of IL-2 correlates with
the occupancy of cis sequences for specific upstream factors (e.g.,
NF-AT). In contrast, the TATA box region and downstream core promoter
sequences were found to be occupied both in resting and activated T
cells, with only minor changes in the in vivo footprinting
pattern around the initiation site in response to gene activation by
ionomycin and phorbol ester. Importantly, protein binding at the core
promoter region could not be detected in pro-myelocytic HL-60 cells
that are incapable of synthesizing IL-2 (91).
Taken together, these observations suggest that the presence or absence
of TFIID at core promoter sequences may determine the expression
capabilities of certain genes, but may not necessarily be indicative of
ongoing initiation. Studying in vivo promoter occupancy by
TFIID on tightly regulated promoters may therefore serve to distinguish
"poised and rapidly inducible" from "inactive" genes. Which
genes are "poised" is likely to be controlled in a tissue and
cell type-specific manner, and may indeed be characteristic (and
therefore diagnostic) for particular cell lineages. This issue is of
particular interest in studies that are aimed at understanding the
molecular basis for cell fate restriction/commitment in development, as well as the imprinting of gene expression patterns to successive generations. Thus, just as stably bound TFIIIA was originally proposed
to be responsible for persistent and preferential expression of somatic
5S ribosomal RNA genes (relative to oocyte-type genes) during
Xenopus development (92), stable TFIID-core promoter complexes on a subset of class II genes might similarly determine an
inheritable gene expression program.
As argued above, an analysis of core promoter occupancy of a given gene
may be indicative of the relevant mechanism of gene regulation.
Although the operative mechanism could be cell type-dependent, core
promoter occupancy data from a large number of genes may nonetheless
allow for a promoter classification scheme that is based on functional
criteria (i.e., the mechanism of regulation), rather than the presence
or absence of poorly conserved (i.e., poorly identifiable) core
promoter elements such as TATA and initiator elements. We speculate
that such a classification scheme of genes may more reliably correlate
promoter regulation with transcriptional cofactor requirement (e.g.,
TAFII250) and, possibly, the function of the gene product
(e.g., a cell cycle regulator, see below).
In addition to studies
supporting the idea that activators can function on preassembled core
promoter complexes as summarized above, there is accumulating evidence
for an important role of activator-mediated changes in the topology of
the TFIID-promoter complex during the activation process.
Activator-induced isomerization of the TFIID nucleoprotein complex in
response to either a natural (15) or an artificial activator (50) was
originally discovered in studies of the Ad5E4 promoter. Importantly and
as mentioned above, the activator-induced conformational change of the
TFIID-Ad5E4 core promoter complex was shown to correlate with enhanced
binding of remaining GTFs and RNA polymerase II (15, 49). More
recently, detailed studies using highly purified components have
further emphasized activator-induced isomerization of the
TFIID-TFIIA-core promoter complex as an important step in
transcription activation (52, 53, 93). Whether topological changes in
the human TFIID-Ad2ML core promoter complex that are induced by the
general coactivator TFIIA, recently demonstrated by site-specific
crosslinking (62), are necessary or sufficient for enhanced PIC
assembly remains to be investigated; but the fact that such
conformational changes are not easily discernible by simple nuclease
protection assays implies that activator- or coactivator-induced
isomerization of the TFIID nucleoprotein complex may be more common
than previously assumed.
The functional analysis of distinct conformational states of TFIID
would clearly be facilitated if the TFIID-core promoter complex could
be locked in a particular conformation. Covalent modification of TFIID
subunits or cofactor binding to the complex (as discussed further in
iv) may have such an effect, without compromising DNA
binding per se, and would thus prove immensely useful as
experimental tools. Likewise, in vitro studies with partially assembled TFIID complexes (23) may be used to shed light on
the roles of individual TFIID subunits in core promoter interactions
and conformational changes of the complex in response to
transcriptional activators.
A number of studies have
noted the role of the core promoter sequence in determining the extent
and selectivity of activator function in vitro and
in vivo (see references in refs. 9 and 11). Differential
binding of TFIID to different core promoters (4-7, 94) and the ability
of promoter-bound TFIID to undergo conformational changes in response
to activator or coactivator interactions (15, 52, 53, 62, 93) argue
strongly for a role of TAFs in the function of core promoter sequences.
Our model implies that the DNA sequence and topological characteristics of a given core promoter will also determine the mechanistic
consequences of activator interactions with TFIID subunits Topological aspects of promoter DNA have been shown in
vitro to affect both basal promoter activity (95, 96) and
transcriptional activation (97), as well as TFIID binding (98, 99).
Furthermore, promoter topology may affect GTF requirements in a core
promoter sequence-specific manner (100, 101).
Given that the sequence of a promoter may dictate its capacity to be
activated through conformational changes of the TFIID-core promoter
complex, the architecture of the TFIID complex and its DNA interaction
surfaces should similarly determine the extent and mechanism of
activation. Indeed, mutations that affect activator-dependent (but not
basal) transcription have been mapped to the DNA interaction surface of
yeast TBP (102, 103), implying that these residues are important for
DNA contacts predominantly in an activator-driven pathway. Similarly,
it may be possible to identify specific TAF mutations that affect
either direct DNA interactions or the stereospecific arrangement of the
TFIID nucleoprotein complex and that selectively affect the function
either of specific activators or of specific core promoters per
se. First indications that this may be a valid prediction come
from studies of a temperature-sensitive allele of human
TAFII250 that selectively affects the function of specific activators on the cyclin D1 promoter (104) and from studies in yeast
indicating that TAF requirements for the activation of specific genes
are determined by core promoter sequences (refs. 27 and 127; reviewed
in refs. 29 and 105).
There are at least two
possible mechanisms, covalent modification by specific enzymatic
activities and stoichiometric binding of cofactors, that may reversibly
affect the ability of the TFIID-core promoter complex to undergo
conformational change.
As mentioned above, it was shown recently that TBP and associated
TAFIIs are phosphorylated in HeLa cells during mitosis, an
event that coincides with the loss of activator-dependent TFIID function in vitro (81). Importantly, the
activator-independent (basal) transcription activity of TFIID was not
significantly reduced, suggesting that phosphorylation of TFIID
subunits does not inhibit TFIID promoter binding per se
but rather affects productive activator interactions or the mechanistic
consequences thereof (81).
Repressors bound to the TFIID-promoter complex could inhibit binding
of the remaining GTFs either directly by steric hindrance or indirectly
by altering the topology of the TFIID-promoter complex. Thus, the
repressor NC2 (Dr1/DRAP1) binds directly to TFIIA interaction sites
on TBP to inhibit TBP-TFIIA-DNA complex formation (64, 66). This
interaction in turn results in significant conformational changes
within the TBP-DNA complex that inhibit efficient recruitment of TFIIB
(67, 68).
Conversely, TFIIA, originally characterized as a GTF, has more recently
been implicated as an important coactivator molecule (52, 53, 64, 93,
106). In addition, TFIIA recruitment to the TFIID-DNA complex is
accompanied by a dramatic conformational change in the complex (62,
107). Thus, specific mutations in TFIIA (106, 108) may be used to
delineate the functional role of TFIIA in activator-induced
isomerization of the TFIID-core promoter complex and to determine
whether these conformational changes are intrinsic to TFIIA's
coactivator function.
Although TFIID can interact with, and function through, downstream core
promoter DNA, with preference for the initiator element consensus
(109), a number of additional initiator-binding proteins have been
identified (10). While their specific requirements in accurate
initiation remain unclear, we imagine that they could in fact function
as coactivators by affecting the conformation of the TFIID-core
promoter complex.
Finally, by analogy to recently described factors (SWI/SNF, NURF,
RSC) that affect nucleosome positioning and stability (110, 111),
coactivators (e.g., GCN5, P/CAF, CBP/p300, or indeed TFIID's own
TAFII250) that exhibit histone-acetyltransferase activity (112) could also modulate activator-dependent conformational changes of
the TFIID-promoter complex or subsequent steps of activator function.
At present, it cannot be ruled out that the as yet biochemically poorly
defined coactivators PC2 and PC5 may contain similar enzymatic activities. Order-of-addition experiments indicate that they act at a
step subsequent to TFIID-TFIIA-DNA complex formation (113).
The sheer complexity of the
eukaryotic general transcription machinery has discouraged comparisons
to eubacterial initiation mechanisms. In eubacteria (Fig.
2A), initiation
requires association of the core RNA polymerase with a single sigma
factor; this interaction triggers a conformational change in sigma that
enables the holoenzyme to recognize the
In eukaryotes, it was originally speculated that TFIID might play a
sigma-like role in class II transcription by virtue of its recognition
of a T/A-rich promoter element. However, TFIID remains associated
with the core promoter after transcription initiation, at least
in vitro (44, 63, 116), and the crystallographic structures
of TBP and sigma rule out any evolutionary relatedness between these
proteins (38, 117). On the other hand, certain regions of TFIIF and
sigma are related in sequence and function (118, 119), and studies of
promoter recognition and start site selection by the core RNA
polymerase, as well as cycling in reinitiation, argue for a sigma-like
role of TFIIB (120). Interestingly, recent genetic and biochemical
studies have suggested that TFIIB and TFIIF, as well as other GTFs, may
associate with RNA polymerase II prior to PIC formation (121); however,
the exact composition of an eukaryotic holoenzyme complex remains
controversial (122, 123). Despite the observations that TFIIF contains
a cryptic sigma-like DNA-binding domain (119) and that template-bound
activators can interact with holoenzyme components (124), the
nucleosomal organization of chromatin may still inhibit access of
GTFs/RNA polymerase II or the holoenzyme complex to some promoters.
Within the more physiological context of a chromatin template, a
constitutive TFIID-core promoter complex may function on some genes to
regulate promoter access and recognition by eukaryotic RNA polymerase
and cognate GTFs (Fig. 2B). In this model, the TFIID-core promoter complex within the chromatin template does not
allow TFIIB-mediated binding of GTFs/RNA polymerase II in the absence
of activators, whereas an activator-effected conformational change
renders the complex capable of supporting subsequent steps of the
initiation pathway. These steps may also be modulated by additional
activator-GTF interactions through a direct recruitment mechanism.
Based on these considerations, certain parallels and differences
between transcription mechanisms in eubacteria and eukaryotes are
evident. Thus, whereas eubacterial holoenzymes are capable of binding
the naked promoter DNA (Fig. 2A), eukaryotic GTFs
and RNA polymerase II (or preassembled holoenzymes) require TFIID bound
to the promoter to access the template (Fig.
2B) Summary
We have proposed that on certain promoters the TFIID-promoter
complex may serve as a specialized nucleoprotein complex that allows
recruitment of RNA polymerase II and downstream GTFs, or a preassembled
holoenzyme, to a chromatin template. Such a notion is remarkably
consistent with interpretations of the earliest successful attempt to
reconstitute accurate transcription initiation on a eukaryotic gene in
a cell-free system. In this case, a purified RNA polymerase III was
shown to support accurate initiation on specific (5S RNA) genes in a
natural chromatin template but not on a purified template DNA (125).
Similarly, RNA polymerase II and GTFs were shown to be capable of
mutual association and subsequent PIC assembly on a template that was
"committed" by prior binding of TFIID (63, 126).
Alongside chromatin packaging components such as nucleosomes, whose own
regulatory functions in gene expression are increasingly recognized,
TFIID has evolved in eukaryotes to provide mechanisms for promoter
recognition by the class II transcription machinery. In this context, a
stable TFIID-core promoter complex regulating promoter accessibility
through conformational changes, as proposed by our model, may be
regarded as a specialized "nucleosome-like" protein-DNA complex.
Thus, such a structure may contribute to packaging of promoter DNA
within chromatin and provide a means for regulated access of RNA
polymerase and GTFs to the template. This is achieved both by excluding
nucleosomes from the core promoter and, more importantly, by virtue of
alternative TFIID-promoter conformations that can be reversibly
affected by activators, transcriptional cofactors and posttranslational
modifications.
What role does activator-effected recruitment of TFIID, as observed
in vitro, have in the proposed scenario of TFIID as a constitutively bound chromatin component? While we have argued that
inducible gene regulation and fine control of gene activity is not
necessarily the result of regulating TFIID access to the DNA, the
apparent heterogeneity of core promoters and gene- and cell
type-specific regulatory proteins suggests a large diversity of
regulatory mechanisms. Moreover, even for those promoters showing stably bound TFIID in specific cell types, certain activators may still
effectively recruit TFIID to the core promoter during differentiation
or at a specific point in the cell cycle (e.g., during the
establishment of a nascent chromatin structure in S phase).
As studies of the transcription field have expanded from determining
in vitro factor requirements on model templates to include an understanding of their functions in the physiological context, we
believe that experimental techniques, interpretations and working hypotheses must reflect the shifted priorities. It is with this intention that we have put forward the present model. Its potential value will depend upon its ability to encourage and to provide a
framework for diverse experimental efforts directed to further our
understanding of TFIID's physiological roles and mechanisms of
function.
Proc. Natl. Acad. Sci. USA
Vol. 94,
pp. 8928-8935,
August 1997
Review
47 to +35, whereas the other (on the
human hsp70 promoter) is restricted to a narrow region over the TATA
element (4). While the TATA box is thought to be the primary site of
specific DNA binding by TFIID, downstream interactions have been shown
to be sequence-dependent as well (5-9). Such interactions could
contribute to TATA-independent modes of TFIID binding to core promoters
(reviewed in ref. 10). This latter notion is further substantiated by
the demonstration that TATA-binding protein (TBP)-associated factors
(TAFs) are required for basal transcription from TATA-less promoters
(11) and, further, that the TATA-specific DNA-binding activity of TBP is dispensable for transcription initiation from TATA-less promoters (12).
both in
experimental design and in interpretation
of the topological state and
organization of the physiological promoter-containing template. It thus
is not surprising that several transcriptional cofactors have been identified as chromatin components, their evolutionary relatives, or
their regulators. Finally, recent studies have also established a
structural and biochemical relationship of the GTF TFIID with protein
components of the nucleosome. Here, we attempt to accommodate these
findings in a novel model to describe a possible physiological mode of
function for TFIID in transcriptional regulation. It may be stated as
follows:
Fig. 1.
States of gene expression. Within physiological
chromatin, each class II gene may be present in any one of three states
that thereby determines its capacity to be transcribed. (A)
"Inactive" genes are packaged in nucleosomes and inaccessible to
the transcription machinery. PIC assembly and initiation must be
preceded by major chromatin remodeling that, in some cases, may require
DNA synthesis and mitosis. (B) "Poised" genes contain
TFIID bound to the core promoter region and thus are rapidly inducible
though otherwise inactive. The conformation of this complex, in the
absence of an inducing stimulus (activator) renders the promoter
inaccessible to RNA polymerase II and other GTFs (or the holoenzyme).
(C) "Active" genes contain promoter-bound activators
that recruit RNA polymerase II and GTFs (or the holoenzyme) either
(i) "indirectly," by inducing a conformational
change in the TFIID-core promoter complex that renders the initiation
region accessible or (ii) "directly," via protein-protein interactions with these components.
[View Larger Version of this Image (19K GIF file)]
for
example, by affecting the ability of the TFIID-core promoter complex
to undergo conformational changes.
10 and
35 elements of the
promoter (114). Promoter binding or function of the holoenzyme may be
aided by activator proteins via specific interactions with different
holoenzyme subunits (reviewed in refs. 105 and 115). Following
initiation of transcription, sigma factor dissociates from the
elongating polymerase and is free to associate with free core RNA
polymerase molecules for subsequent rounds of promoter recognition and
transcription initiation.
Fig. 2.
Universal aspects in transcription initiation
mechanisms. (A) Initiation in eubacteria requires the
binding of a sigma factor to the RNA polymerase (Pol) to form the
holoenzyme. This event induces a conformational change in the sigma
factor, enabling it to recognize specific sequences of proximal
promoter elements, leading to transcription initiation. Activators may
facilitate this recognition step through interactions with holoenzyme
components. (B) Initiation on class II promoters may involve
analogous steps of holoenzyme assembly with GTFs binding to RNA
polymerase II (Pol II), depicted here to emphasize parallels to the
eubacterial paradigm. This holoenzyme (or RNA polymerase II and unbound
GTFs) is able to recognize the initiation region via TFIID, but only when TFIID is bound to the core promoter DNA in a particular
conformation(s) and not in another(s). The transcriptionally active
conformation of TFIID can be induced by a large variety of
upstream-bound activators via the coactivator function of certain TAFs
and soluble cofactors.
[View Larger Version of this Image (19K GIF file)]
such that certain stable TFIID-promoter
complexes (within the chromatin context) may be formally equivalent to
the eubacterial DNA template. Further, whereas recruitment of the
eubacterial holoenzyme to cognate promoters may or may not require
activators, the physiological assembly of functional PICs in eukaryotic
cells generally requires activators both for "direct" and
"indirect" (via the TFIID-core promoter complex) recruitment
mechanisms.
*
To whom reprint requests should be sent at the present address:
Department of Biology, Massachusetts Institute of Technology, 68-380, 77 Massachusetts Avenue, Cambridge, MA 02139. e-mail: alexhoff{at}mit.edu.
We are grateful to many of our colleagues and collaborators, particularly Drs. A. J. Koleske, E. Martinez, N. Segil, S. K. Burley, N. Heintz, and J. E. Darnell, Jr. for stimulating discussions and/or critical reading of the manuscript. A.H. thanks D. Baltimore for his encouragement and support.
TBP, TATA binding protein; TAF, TBP-associated factor; PIC, preinitiation complex; GTF, general transcription factor; Ad, adenovirus.
| 1. |
Matsui, T., Segall, J., Weil, P. A. & Roeder, R. G.
(1980)
J. Biol. Chem.
255,
11992-11996
|
| 2. | Parker, C. S. & Topol, J. (1984) Cell 36, 357-369 [CrossRef][ISI][Medline] . |
| 3. | Sawadogo, M. & Roeder, R. G. (1985) Cell 43, 165-175 [CrossRef][ISI][Medline] . |
| 4. |
Nakajima, N., Horikoshi, M. & Roeder, R. G.
(1988)
Mol. Cell. Biol.
8,
4028-4040
|
| 5. | Nakatani, Y., Horikoshi, M., Brenner, M., Yamamoto, T., Besnard, F., Roeder, R. G. & Freese, E. (1990) Nature (London) 348, 86-88 [CrossRef][Medline] . |
| 6. | Verrijzer, C. P., Chen, J.-L., Yokomori, K. & Tjian, R. (1995) Cell 81, 1115-1125 [CrossRef][ISI][Medline] . |
| 7. |
Burke, T. W. & Kadonaga, J. T.
(1996)
Genes Dev.
10,
711-724
|
| 8. | Wang, J. C. & van Dyke, M. W. (1993) Biochim. Biophys. Acta 1216, 73-80 [Medline] . |
| 9. |
Kaufmann, J. & Smale, S. T.
(1994)
Genes Dev.
8,
821-829
|
| 10. | Roeder, R. G. (1996) Trends Biochem. Sci. 21, 327-335 [CrossRef][ISI][Medline] . |
| 11. | Martinez, E., Chiang, C.-M., Ge, H. & Roeder, R. G. (1994) EMBO J. 13, 3115-3126 [ISI][Medline] . |
| 12. |
Martinez, E., Zhou, Q., L'Etoile, N., Oelgeschläger, T., Berk, A. J. & Roeder, R. G.
(1995)
Proc. Natl. Acad. Sci. USA
92,
11864-11868
|
| 13. |
Abmayr, S. M., Workman, J. L. & Roeder, R. G.
(1988)
Genes Dev.
2,
542-553
|
| 14. | Workman, J. L., Abmayr, S. M., Cromlish, W. A. & Roeder, R. G. (1988) Cell 55, 211-219 [CrossRef][ISI][Medline] . |
| 15. | Horikoshi, M., Hai, T., Lin, Y.-S., Green, M. R. & Roeder, R. G. (1988) Cell 54, 1033-1042 [CrossRef][ISI][Medline] . |
| 16. | Hoffmann, A., Sinn, E., Yamamoto, T., Wang, J., Roy, A., Horikoshi, M. & Roeder, R. G. (1990) Nature (London) 346, 387-390 [CrossRef][Medline] . |
| 17. |
Peterson, M. G., Tanese, N., Pugh, B. F. & Tjian, R.
(1990)
Science
248,
1625-1630
|
| 18. | Pugh, B. F. & Tjian, R. (1990) Cell 61, 1187-1197 [CrossRef][ISI][Medline] . |
| 19. | Burley, S. K. & Roeder, R. G. (1996) Annu. Rev. Biochem. 65, 769-799 [CrossRef][ISI][Medline] . |
| 20. | Goodrich, J. A., Hoey, T., Thut, C. J., Admon, A. & Tjian, R. (1993) Cell 75, 519-530 [CrossRef][ISI][Medline] . |
| 21. | Hoey, T., Weinzierl, R. O. J., Gill, G., Chen, J.-L., Dynlacht, B. D. & Tjian, R. (1993) Cell 72, 247-260 [CrossRef][ISI][Medline] . |
| 22. |
Chiang, C.-M. & Roeder, R. G.
(1995)
Science
267,
531-536
|
| 23. | Chen, J.-L., Attardi, L. D., Verrijzer, C. P., Yokomori, K. & Tjian, R. (1994) Cell 79, 93-105 [CrossRef][ISI][Medline] . |
| 24. | Jacq, X., Brou, C., Lutz, Y., Davidson, I., Chambon, P. & Tora, L. (1994) Cell 79, 107-117 [CrossRef][ISI][Medline] . |
| 25. |
Gill, G., Pascal, E., Tseng, Z. H. & Tjian, R.
(1994)
Proc. Natl. Acad. Sci. USA
91,
192-196
|
| 26. | Sauer, F., Wassarman, D. A., Rubin, G. M. & Tjian, R. (1996) Cell 87, 1271-1284 [CrossRef][Medline] . |
| 27. | Moqtaderi, Z., Bai, Z., Poon, D., Weil, P. A. & Struhl, K. (1996) Nature (London) 383, 188-191 [CrossRef][Medline] . |
| 28. | Walker, S. S., Reese, J. C., Apone, L. M. & Green, M. R. (1996) Nature (London) 383, 185-188 [CrossRef][Medline] . |
| 29. | Tansey, W. P. & Herr, W. (1997) Cell 88, 729-732 [CrossRef][ISI][Medline] . |
| 30. | Kaiser, K. & Meisterernst, M. (1996) Trends Biochem. Sci. 21, 342-345 [CrossRef][ISI][Medline] . |
| 31. | Blair, W. S., Fridall, R. A. & Cullen, B. R. (1996) EMBO J. 15, 1658-1665 [ISI][Medline] . |
| 32. | Blau, J., Xiao, H., McCracken, S., O'Hare, P., Greenblatt, J. & Bentley, D. L. (1996) Mol. Cell. Biol. 16, 2044-2055 [Abstract]. |
| 33. | McClure, W. R. (1985) Annu. Rev. Biochem. 54, 171-204 [CrossRef][ISI][Medline] . |
| 34. | Koleske, A. J. & Young, R. A. (1995) Trends Biochem. Sci. 20, 113-116 [CrossRef][ISI][Medline] . |
| 35. | Stringer, K. F., Ingles, C. J. & Greenblatt, J. (1990) Nature (London) 345, 783-786 [CrossRef][Medline] . |
| 36. | Ingles, C. J., Shales, M., Cress, W. D., Triezenberg, S. J. & Greenblatt, J. (1991) Nature (London) 351, 588-590 [CrossRef][Medline] . |
| 37. | Wu, Y., Reece, R. J. & Ptashne, M. (1996) EMBO J. 16, 3951-3963 . |
| 38. | Nikolov, D. B. & Burley, S. K. (1994) Nat. Struct. Biol. 1, 621-637 [CrossRef][ISI][Medline] . |
| 39. | Lin, Y. S., Carey, M., Ptashne, M. & Green, M. R. (1990) Nature (London) 345, 359-361 [CrossRef][Medline] . |
| 40. |
Sauer, F., Hansen, S. K. & Tjian, R.
(1995)
Science
270,
1783-1788
|
| 41. |
Sauer, F., Hansen, S. K. & Tjian, R.
(1995)
Science
270,
1825-1828
|
| 42. |
Fire, A., Samuels, M. & Sharp, P. A.
(1984)
J. Biol. Chem.
259,
2509-2516
|
| 43. |
Hawley, D. K. & Roeder, R. G.
(1985)
J. Biol. Chem.
260,
8163-8172
|
| 44. |
van Dyke, M. W., Sawadogo, M. & Roeder, R. G.
(1989)
Mol. Cell. Biol.
9,
342-344
|
| 45. | Workman, J. L. & Roeder, R. G. (1987) Cell 51, 613-622 [CrossRef][ISI][Medline] . |
| 46. |
Huang, D.-H., Horikoshi, M. & Roeder, R. G.
(1988)
J. Biol. Chem.
263,
12596-12601
|
| 47. |
Schmidt, M. C., Zhou, Q. & Berk, A. J.
(1989)
Mol. Cell. Biol.
9,
3299-3307
|
| 48. | White, J., Brou, C., Wu, J., Lutz, Y., Moncollin, V. & Chambon, P. (1992) EMBO J. 11, 2229-2240 [ISI][Medline] . |
| 49. | Hai, T., Horikoshi, M., Roeder, R. G. & Green, M. (1988) Cell 54, 1043-1051 [CrossRef][ISI][Medline] . |
| 50. | Horikoshi, M., Carey, M. F., Kakidani, H. & Roeder, R. G. (1988) Cell 54, 665-669 [CrossRef][ISI][Medline] . |
| 51. | Lin, Y. S. & Green, M. R. (1991) Cell 64, 971-981 [CrossRef][ISI][Medline] . |
| 52. | Chi, T., Lieberman, P., Ellwood, K. & Carey, M. (1995) Nature (London) 377, 254-257 [Medline] . |
| 53. |
Chi, T. & Carey, M.
(1996)
Genes Dev.
10,
2540-2550
|
| 54. | Kim, Y., Geiger, J. H., Hahn, S. & Sigler, P. B. (1993) Nature (London) 365, 512-520 [CrossRef][Medline] . |
| 55. | Kim, J. L., Nikolov, D. B. & Burley, S. K. (1993) Nature (London) 365, 520-527 [CrossRef][Medline] . |
| 56. | Nikolov, D. B., Chen, H., Halay, E. D., Usheva, A. A., Hisatake, K., Lee, D. K., Roeder, R. G. & Burley, S. K. (1995) Nature (London) 377, 119-128 [CrossRef][Medline] . |
| 57. | Geiger, J. H., Hahn, S., Lee, S. & Sigler, P. B. (1996) Science 272, 830-836 [Abstract]. |
| 58. | Tan, S., Hunzikar, Y., Sargent, D. F. & Richmond, T. J. (1996) Nature (London) 381, 127-134 [CrossRef][Medline] . |
| 59. | Hoffmann, A., Chiang, C.-M., Oelgeschläger, T., Xie, X., Burley, S. K., Nakatani, Y. & Roeder, R. G. (1996) Nature (London) 380, 356-359 [CrossRef][Medline] . |
| 60. | Xie, X., Kokubo, T., Cohen, S. L., Mirza, U. A., Hoffmann, A., Chait, B. T., Roeder, R. G., Nakatani, Y. & Burley, S. K. (1996) Nature (London) 380, 316-322 [CrossRef][Medline] . |
| 61. |
Hoffmann, A. & Roeder, R. G.
(1996)
J. Biol. Chem.
271,
18194-18202
|
| 62. | Oelgeschläger, T., Chiang, C.-M. & Roeder, R. G. (1996) Nature (London) 382, 735-738 [CrossRef][Medline] . |
| 63. |
van Dyke, M. W., Roeder, R. G. & Sawadogo, M.
(1988)
Science
241,
1335-1338
|
| 64. | Meisterernst, M. & Roeder, R. G. (1991) Cell 67, 557-567 [CrossRef][ISI][Medline] . |
| 65. | Inostroza, J. A., Mermelstein, F. H., Ha, I., Lane, W. S. & Reinberg, D. (1992) Cell 70, 477-489 [CrossRef][ISI][Medline] . |
| 66. |
Kim, T. K., Zhao, Y., Ge, H., Bernstein, R. & Roeder, R. G.
(1995)
J. Biol. Chem.
270,
10976-10981
|
| 67. | Goppelt, A., Stelzer, G., Lottspeich, F. & Meisterernst, M. (1996) EMBO J. 15, 3105-3116 [ISI][Medline] . |
| 68. |
Mermelstein, F., Yeung, K., Cao, J., Inostroza, J. A., Erdjument-Bromage, H., Eagelson, K., Landsman, D., Levitt, P., Tempst, P. & Reinberg, D.
(1996)
Genes Dev.
10,
1033-1048
|
| 69. |
Gadbois, E. L., Chao, D. M., Reese, J. C., Green, M. R. & Young, R. A.
(1997)
Proc. Natl. Acad. Sci. USA
94,
3145-3150
|
| 70. |
Kretzschmar, M., Meisterernst, M. & Roeder, R. G.
(1993)
Proc. Natl. Acad. Sci. USA
90,
11508-11512
|
| 71. | Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J. & Reinberg, D. (1993) Nature (London) 365, 227-232 [CrossRef][Medline] . |
| 72. |
Shykind, B. M., Kim, J., Stance, L., Champoux, J. J. & Sharp, P. A.
(1997)
Genes Dev.
11,
397-407
|
| 73. |
Ge, H. & Roeder, R. G.
(1994)
J. Biol. Chem.
269,
17136-17140
|
| 74. |
Shykind, B. M., Kim, J. & Sharp, P. A.
(1995)
Genes Dev.
9,
1354-1365
|
| 75. |
Stelzer, G., Goppelt, A., Lottspeich, F. & Meisterernst, M.
(1994)
Mol. Cell. Biol.
14,
4712-4721
|
| 76. |
Paranjape, S. M., Krumm, A. & Kadonaga, J. T.
(1995)
Genes Dev.
9,
1978-1991
|
| 77. | Thanos, D. & Maniatis, T. (1992) Cell 71, 777-789 [CrossRef][ISI][Medline] . |
| 78. | Love, J. J., Li, X., Case, D. A., Giese, K., Grosschedl, R. & Wright, P. E. (1995) Nature (London) 376, 791-795 [CrossRef][Medline] . |
| 79. | Lehming, N., Thanos, D., Brickman, J. M., Ma, J., Maniatis, T. & Ptashne, M. (1994) Nature (London) 371, 175-179 [CrossRef][Medline] . |
| 80. |
Bortvin, A. & Winston, F.
(1996)
J. Biol. Chem.
272,
1473-1476
|
| 81. |
Segil, N., Guermah, M., Hoffmann, A., Roeder, R. G. & Heintz, N.
(1996)
Genes Dev.
10,
2389-2400
|
| 82. |
Segil, N., Roberts, S. B. & Heintz, N.
(1991)
Science
254,
1814-1816
|
| 83. | Dikstein, R., Ruppert, S. & Tjian, R. (1996) Cell 84, 781-790 [CrossRef][ISI][Medline] . |
| 84. | Mizzen, C. A., Yang, X.-J., Kokubo, T., Brownell, J. E., Bannister, A. J., Owen-Hughes, T., Workman, J., Wang, L., Berger, S. L., Kazourides, T., Nakatani, Y. & Allis, C. D. (1996) Cell 87, 1261-1270 [CrossRef][ISI][Medline] . |
| 85. | Kuo, M.-H., Brownell, J. E., Sobel, R. E., Ranalli, T. A., Cook, R. G., Edmonson, D. G., Roth, S. Y. & Allis, C. D. (1996) Nature (London) 383, 269-272 [CrossRef][Medline] . |
| 86. | Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H. & Nakatani, Y. (1996) Cell 87, 953-959 [CrossRef][ISI][Medline] . |
| 87. | Ganter, B., Tan, S. & Richmond, T. J. (1993) J. Mol. Biol. 234, 975-987 [CrossRef][Medline] . |
| 88. | Gross, D. S., English, K. E., Collins, K. W. & Lee, S. W. (1990) J. Mol. Biol. 216, 611-631 [CrossRef][ISI][Medline] . |
| 89. |
Weber, J. A. & Gilmour, D. S.
(1995)
Nucleic Acids Res.
23,
3327-3334
|
| 90. |
Chen, J., Ding, M. & Pederson, D. S.
(1994)
Proc. Natl. Acad. Sci. USA
91,
11909-11913
|
| 91. |
Brunvand, M. W., Krumm, A. & Groudine, M.
(1993)
Nucleic Acids Res.
21,
4824-4829
|
| 92. |
Wolffe, A. P. & Brown, D. D.
(1988)
Science
241,
1626-1632
|
| 93. |
Lieberman, P. M. & Berk, A. J.
(1994)
Genes Dev.
8,
995-1006
|
| 94. | Chiang, C.-M., Ge, H., Wang, Z., Hoffmann, A. & Roeder, R. G. (1993) EMBO J. 12, 2749-2762 [ISI][Medline] . |
| 95. |
Mizutani, M., Ura, K. & Hirose, S.
(1991)
Nucleic Acids Res.
19,
2907-2911
|
| 96. |
Hirose, S. & Suzuki, Y.
(1988)
Proc. Natl. Acad. Sci. USA
85,
718-722
|
| 97. |
Mizushima-Sugano, J. & Roeder, R. G.
(1986)
Proc. Natl. Acad. Sci. USA
83,
8511-8515
|
| 98. |
Mizutani, M., Ohta, T., Watanabe, H., Handa, H. & Hirose, S.
(1990)
Proc. Natl. Acad. Sci. USA
88,
718-722
|
| 99. | Parvin, J. D., McCormick, R. J., Sharp, P. A. & Fisher, D. E. (1995) Nature (London) 373, 724-727 [CrossRef][Medline] . |
| 100. | Parvin, J. D., Timmers, H. T. & Sharp, P. A. (1992) Cell 68, 1135-1144 [CrossRef][ISI][Medline] . |
| 101. | Holstege, F. C., Tantin, D., Carey, M., van der Vliet, P. C. & Timmers, H. T. (1995) EMBO J. 14, 810-819 [ISI][Medline] . |
| 102. | Kim, T. K., Hashimoto, S., Kelleher, R. J. I., Flanagan, P. M., Kornberg, R. D., Horikoshi, M. & Roeder, R. G. (1994) Nature (London) 369, 252-255 [CrossRef][Medline] . |
| 103. | Lee, M. & Struhl, K. (1996) Mol. Cell. Biol. 15, 5461-5469 [Abstract]. |
| 104. | Suzuki-Yagawa, Y., Guermah, M. & Roeder, R. G. (1997) Mol. Cell. Biol. 17, 3284-3294 [Abstract]. |
| 105. | Ptashne, M. & Gann, A. (1997) Nature (London) 386, 569-577 [CrossRef][Medline] . |
| 106. |
Ma, D., Olave, I., Merino, A. & Reinberg, D.
(1996)
Proc. Natl. Acad. Sci. USA
93,
6583-6588
|
| 107. |
Wang, W., Gralla, J. D. & Carey, M.
(1992)
Genes Dev.
6,
1716-1727
|
| 108. |
Ozer, J., Bolden, A. H. & Lieberman, P. M.
(1996)
J. Biol. Chem.
271,
11182-11190
|
| 109. |
Purnell, B. A. & Gilmour, D. S.
(1993)
Mol. Cell. Biol.
13,
2593-2603
|
| 110. |
Kingston, R. E., Bunker, C. A. & Imbalzano, A. N.
(1996)
Genes Dev.
10,
905-920
|
| 111. | Cairns, B. R., Lorch, Y., Li, Y., Zhang, M., Lacomis, L., Erdjument-Bromage, H., Tempst, P., Du, J., Laurent, B. & Kornberg, R. D. (1996) Cell 87, 1249-1260 [CrossRef][ISI][Medline] . |
| 112. | Roth, S. Y. & Allis, C. D. (1996) Cell 87, 5-8 [CrossRef][ISI][Medline] . |
| 113. |
Halle, J. P., Stelzer, G., Goppelt, A. & Meisterernst, M.
(1995)
J. Biol. Chem.
270,
21307-21311
|
| 114. | Helmann, J. D. & Chamberlin, M. J. A. (1988) Annu. Rev. Biochem. 57, 839-872 [CrossRef][ISI][Medline] . |
| 115. | Busby, S. & Ebright, R. H. (1994) Cell 79, 743-746 [ISI][Medline] . |
| 116. |
Zawel, L., Kumar, K. P. & Reinberg, D.
(1995)
Genes Dev.
9,
1479-1490
|
| 117. | Malhotra, A., Severinova, E. & Darst, S. A. (1996) Cell 87, 127-136 [CrossRef][ISI][Medline] . |
| 118. |
McCracken, S. & Greenblatt, J.
(1991)
Science
253,
900-902
|
| 119. |
Tan, S., Garrett, K. P., Conaway, R. C. & Conaway, J. W.
(1994)
Proc. Natl. Acad. Sci. USA
91,
9808-9812
|
| 120. |
Killeen, M., Coulombe, B. & Greenblatt, J.
(1992)
J. Biol. Chem.
267,
9463-9466
|
| 121. | Koleske, A. J. & Young, R. A. (1994) Nature (London) 368, 466-469 [CrossRef][Medline] . |